• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    50 Biggest Movers From Yesterday

    1/6/22 5:23:00 AM ET
    $AACG
    $AMBA
    $ANNX
    $APCX
    Other Consumer Services
    Real Estate
    Semiconductors
    Technology
    Get the next $AACG alert in real time by email

    Gainers

    • Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead clinical compound, LB-100, a protein phosphatase inhibitor, was found to increase the responsiveness of diverse cancers to immunotherapy.
    • Mainz Biomed B.V. (NASDAQ:MYNZ) shares jumped 47.4% to close at $15.21 on Wednesday after the company announced it acquired exclusive rights to novel mRNA biomarkers.
    • BTCS Inc. (NASDAQ:BTCS) shares jumped 43.9% to close at $4.36 after the company announced a Bitcoin dividend of $0.05 per share in Bitcoin.
    • Eliem Therapeutics, Inc. (NASDAQ:ELYM) rose 38.3% to settle at $13.15.
    • Data Storage Corporation (NASDAQ:DTST) gained 33.2% to settle at $4.13 after the company announced a multi-million dollar contract with a professional sports team.
    • CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) rose 31.4% to close at $1.05.
    • Vertical Aerospace Ltd. (NYSE:EVTL) climbed 29.1% to close at $9.05.
    • Castlight Health, Inc. (NYSE:CSLT) rose 23.8% to settle at $2.03 after the company, and Vera Whole Health, jointly announced an agreement under which the companies will combine.
    • Edgewise Therapeutics, Inc. (NASDAQ:EWTX) gained 22.5% to settle at $18.97 after the company announced topline results from the EDG-5506 Phase 1b clinical trial in adults with Becker muscular dystrophy.
    • BioVie Inc. (NASDAQ:BIVI) gained 15.8% to close at $5.65.
    • XOMA Corporation (NASDAQ:XOMA) gained 12.7% to settle at $23.00.
    • Insignia Systems, Inc. (NASDAQ:ISIG) climbed 12.5% to close at $20.12.
    • Ecoark Holdings, Inc. (NASDAQ:ZEST) shares jumped 10.5% to settle at $2.73.
    • Stereotaxis, Inc. (NYSE:STXS) gained 8.7% to close at $6.63. Craig-Hallum and Loop Capital initiated coverage on the stock with Buy ratings.
    • Vicinity Motor Corp. (NASDAQ:VEV) rose 6.5% to close at $3.62 as the company received $19 million order for over 150 VMC Optimal E1 Electric Chassis.
    • Wejo Group Ltd (NASDAQ:WEJO) gained around 5% to settle at $6.61 after the company announced a new connected vehicle platform with Microsoft, called Wejo Neural Edge.


    Check out these big penny stock gainers and losers

    Losers

    • AppTech Payments Corp. (NASDAQ:APCX) shares dipped 83.2% to close at $2.30 on Wednesday after the company reported pricing of $15.0 million underwritten public offering and Nasdaq listing.
    • Annexon, Inc. (NASDAQ:ANNX) shares fell 34.1% to close at $7.26 after the company announced interim data from its ongoing, open-label Phase 2 clinical trial of ANX005 in patients with Huntington's disease who completed the 24-week treatment period.
    • Applied Therapeutics, Inc (NASDAQ:APLT) fell 23.5% to settle at $4.45. Barclays recently downgraded Applied Therapeutics from Overweight to Equal-Weight and lowered the price target from $44 to $7.
    • Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) dropped 22.6% to settle at $15.63.
    • Nutriband Inc. (NASDAQ:NTRB) dipped 22.3% to close at $6.99. Nutriband recently announced the Korean Intellectual Property Office has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the company's lead technology AVERSA.
    • Imago BioSciences, Inc. (NASDAQ:IMGO) fell 21.3% to settle at $19.68. Imago BioSciences, last month, presented data from the ongoing Phase 2 study of bomedemstat in essential thrombocythemia at ASH 2021.
    • GoHealth, Inc. (NASDAQ:GOCO) fell 20.7% to close at $3.26 after B of A Securities downgraded the stock from Buy to Underperform and lowered its price target from $7.5 to $3.5.
    • Tenaya Therapeutics, Inc. (NASDAQ:TNYA) dropped 20.6% to settle at $14.52.
    • Sino-Global Shipping America, Ltd. (NASDAQ:SINO) fell 20.6% to close at $4.12.
    • Arcadia Biosciences, Inc. (NASDAQ:RKDA) shares dipped 19.4% to close at $1.12. The company was recently granted a notice of allowance for a US patent titled 'Wheat Having Resistance to Glyphosate Due to Alterations in 5-Enol-Pyruvylshikimate-3 Phosphate Synthase.'
    • Ambarella, Inc (NASDAQ:AMBA) dipped 19.3% to close at $165.40. Ambarella unveiled artificial intelligence image signal processor at CES.
    • Genprex, Inc. (NASDAQ:GNPX) fell 18.6% to settle at $2.27. Genprex recently expanded gene therapy oncology pipeline to include small cell lung cancer.
    • ReTo Eco-Solutions, Inc. (NASDAQ:RETO) dropped 18.4% to close at $1.42. ReTo Eco-Solutions recently announced it entered into an Equity Acquisition Agreement with Hainan REIT Mingde Investment Holding Co.
    • Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) dipped 18.2% to close at $1.77. Infinity Pharmaceuticals outlined Eganelisib clinical development strategy.
    • Bakkt Holdings, Inc. (NYSE:BKKT) dropped 17.8% to close at $6.19.
    • Pingtan Marine Enterprise Ltd. (NASDAQ:PME) fell 17.6% to settle at $0.5274.
    • Vera Therapeutics, Inc. (NASDAQ:VERA) tumbled 17.5% to close at $22.32. Vera Therapeutics, last month, reported purchase of monoclonal antibody from Pfizer.
    • Viant Technology Inc. (NASDAQ:DSP) dropped 17.3% to settle at $8.09.
    • AvidXchange Holdings, Inc. (NASDAQ:AVDX) fell 16.7% to close at $13.11.
    • TransCode Therapeutics, Inc. (NASDAQ:RNAZ) fell 16.6% to close at $2.51.
    • Singular Genomics Systems, Inc. (NASDAQ:OMIC) dipped 16.6% to settle at $9.07.
    • Flora Growth Corp. (NASDAQ:FLGC) fell 16.2% to close at $1.81. Flora recently announced it expanded its product distribution through Walmart.com and Coppel in Mexico.
    • Biomea Fusion, Inc. (NASDAQ:BMEA) fell 15.8% to close at $7.47.
    • TD Holdings, Inc. (NASDAQ:GLG) dropped 15.5% to settle at $0.3973.
    • SMART Global Holdings, Inc (NASDAQ:SGH) fell 15.4% to close at $61.52. SMART Global Holdings reported upbeat results for its first quarter on Tuesday. The company said it sees Q2 adjusted earnings of $1.30 to $1.60 per share on sales of $415 million to $455 million.
    • Ikena Oncology, Inc. (NASDAQ:IKNA) dipped 15.4% to close at $11.72.
    • Entrada Therapeutics, Inc. (NASDAQ:TRDA) dropped 15.4% to settle at $13.53.
    • Blueprint Medicines Corporation (NASDAQ:BPMC) fell 12.8% to close at $93.30.
    • Connect Biopharma Holdings Limited (NASDAQ:CNTB) dipped 12.3% to close at $5.00. Connect Biopharma reported detailed dataset from global Phase 2b trial of CBP-201 in adult patients with moderate-to-severe atopic dermatitis.
    • Applied UV, Inc. (NASDAQ:AUVI) fell 11.6% to close at $2.96.
    • Hoth Therapeutics, Inc. (NASDAQ:HOTH) shares fell 10.8% to settle at $1.16. Hoth Therapeutics shares jumped over 85% on Tuesday after the company announced proof-of-concept data generated using an Alzheimer's disease mouse model, supporting the therapeutic potential of HT-ALZ.
    • ATA Creativity Global (NASDAQ:AACG) fell 9.8% to close at $2.30 after jumping 114% on Tuesday.
    • NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) fell 6.5% to close at $1.44 after jumping more than 16% on Tuesday.
    • Alexandria Real Estate Equities, Inc. (NYSE:ARE) fell 6.4% to close at $206.65 as the company reported pricing of upsized public offering of 7,000,000 shares of common stock.
    Get the next $AACG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AACG
    $AMBA
    $ANNX
    $APCX

    CompanyDatePrice TargetRatingAnalyst
    Entrada Therapeutics Inc.
    $TRDA
    4/1/2026Overweight
    Cantor Fitzgerald
    Alexandria Real Estate Equities Inc.
    $ARE
    3/25/2026$52.00Outperform → Market Perform
    BMO Capital Markets
    Vera Therapeutics Inc.
    $VERA
    3/11/2026$88.00Peer Perform → Outperform
    Wolfe Research
    Vertical Aerospace Ltd.
    $EVTL
    2/23/2026Mkt Perform → Underperform
    Raymond James
    Entrada Therapeutics Inc.
    $TRDA
    2/11/2026$20.00Buy
    Guggenheim
    Alexandria Real Estate Equities Inc.
    $ARE
    2/3/2026$60.00Neutral
    Goldman
    Entrada Therapeutics Inc.
    $TRDA
    1/28/2026$21.00Outperform
    Oppenheimer
    Biomea Fusion Inc.
    $BMEA
    1/13/2026$8.00Buy
    Rodman & Renshaw
    More analyst ratings

    $AACG
    $AMBA
    $ANNX
    $APCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Madden Larry sold $417,239 worth of shares (39,328 units at $10.61) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 553,699 units (SEC Form 4)

    4 - Viant Technology Inc. (0001828791) (Issuer)

    4/23/26 9:03:24 PM ET
    $DSP
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Capital V Llc

    4 - Viant Technology Inc. (0001828791) (Issuer)

    4/22/26 7:58:20 PM ET
    $DSP
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Vanderhook Timothy

    4 - Viant Technology Inc. (0001828791) (Issuer)

    4/22/26 7:58:10 PM ET
    $DSP
    Computer Software: Programming Data Processing
    Technology

    $AACG
    $AMBA
    $ANNX
    $APCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $45,360 worth of shares (8,000 units at $5.67), increasing direct ownership by 15% to 62,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    3/12/26 4:31:34 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Derosa Thomas Joseph bought $3,299 worth of shares (10,000 units at $0.33), increasing direct ownership by 22% to 56,096 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    3/5/26 4:58:08 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    Director Lord Albert L bought $9,578 worth of shares (29,606 units at $0.32), increasing direct ownership by 0.91% to 3,300,000 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    3/5/26 4:57:43 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    $AACG
    $AMBA
    $ANNX
    $APCX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Entrada Therapeutics Inc.

    DEFA14A - Entrada Therapeutics, Inc. (0001689375) (Filer)

    4/24/26 8:31:00 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Entrada Therapeutics Inc.

    DEF 14A - Entrada Therapeutics, Inc. (0001689375) (Filer)

    4/24/26 8:30:13 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Viant Technology Inc.

    DEFA14A - Viant Technology Inc. (0001828791) (Filer)

    4/23/26 4:09:16 PM ET
    $DSP
    Computer Software: Programming Data Processing
    Technology

    $AACG
    $AMBA
    $ANNX
    $APCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stereotaxis Announces First MAGiC Procedures in the United States

    ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the US have been successfully treated using MAGiC™. MAGiC, Stereotaxis' proprietary robotically-navigated magnetic interventional cardiac ablation catheter, recently received Food & Drug Administration PMA approval. It is the first ablation catheter specifically approved to treat arrhythmia in patients with complex congenital heart disease. Dr. Nathan McConkey, Cardiac Electrophysiologist at Oregon Health & Science University, performed the first MAGiC procedure in the United States o

    4/22/26 7:58:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

    AUSTIN, Texas, April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract has been selected for publication at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 – June 2, 2026 in Chicago, Illinois. The abstract details positive clinical data from studies of predictive biomarkers in patients receiving its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of lung cancer.

    4/22/26 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast

    ORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jack Neel Podcast to discuss the opioid crisis, the Company's AVERSA technology and the opportunity for Nutriband to improve the safety profile of easily abused medications. Interested shareholders may find the link to the latest youtube episode here https://youtu.be/HB6E7TxGXqg?si=VU6c57saNbdzxraH. The Episode can also be found on Spotify, iTunes, Amazon music and www.jackneel.com About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology

    4/22/26 7:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    $AACG
    $AMBA
    $ANNX
    $APCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Entrada Therapeutics

    Cantor Fitzgerald initiated coverage of Entrada Therapeutics with a rating of Overweight

    4/1/26 8:36:28 AM ET
    $TRDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alexandria RE downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Alexandria RE from Outperform to Market Perform and set a new price target of $52.00

    3/25/26 8:24:55 AM ET
    $ARE
    Real Estate Investment Trusts
    Real Estate

    Vera Therapeutics upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Vera Therapeutics from Peer Perform to Outperform and set a new price target of $88.00

    3/11/26 8:30:17 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AACG
    $AMBA
    $ANNX
    $APCX
    Financials

    Live finance-specific insights

    View All

    Land & Buildings Announces Investment Opinion: Issues White Paper Detailing Why It Believes Welltower's Compensation Program Is Likely to Lead to Inferior Shareholder Returns

    NOTE TO EDITORS: The Following Is an Investment Opinion Issued by Land & Buildings Investment Management, LLC Welltower Shares Trade at 144% Premium to NAV and 33x FFO: Investors Switching to Ventas or American Healthcare REIT Receive 50% More Asset Value Per Dollar Estimates Shares Could See ~35%-60% Downside From Current Levels to Match Peer Valuations – Discloses Short Position in Welltower Today, Land & Buildings Investment Management, LLC (together with its affiliates, "Land & Buildings," "L&B," "us" or "we"), issued a white paper on Welltower, Inc. (NYSE:WELL) ("Welltower" or the "Company"), titled Compensation Plan Hubris: Why Welltower's Ten-Year Executive Program Is Likely to

    4/21/26 9:05:00 AM ET
    $AHR
    $ARE
    $VTR
    Real Estate Investment Trusts
    Real Estate

    Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026

    ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 first quarter on Tuesday, May 12, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What: Stereotaxis first quarter 2026 financial results conference call   When: Tuesday, May 12, 2026, at 4:30 p.m. ET (1:30 p.m. PT)   Dial In Number: To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (Internati

    4/21/26 9:01:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Viant Announces Agreement to Acquire TVision Strengthening Its AI-Powered Programmatic Platform

    Delivering Advertisers an Unbiased View of the TV Landscape and a Clearer Path to Results Viant Technology Inc. (NASDAQ:DSP), a leader in CTV and AI-powered programmatic advertising, today announced it has entered into a definitive agreement to acquire TVision Insights, the only attention measurement provider delivering second-by-second, eyes-on-screen attention, co-viewership and in-room presence for TV. With this acquisition, Viant strengthens its AI-powered programmatic platform by integrating TVision's proprietary attention signals directly into its buying platform. Combined with Viant's Household ID and IRIS_ID, TVision adds three new critical signals to Viant's Intelligence Layer,

    4/15/26 7:35:00 AM ET
    $DSP
    Computer Software: Programming Data Processing
    Technology

    $AACG
    $AMBA
    $ANNX
    $APCX
    Leadership Updates

    Live Leadership Updates

    View All

    Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

    BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, effective immediately. "Jane has worked with Vera Therapeutics previously as a strategic legal consultant and brings a depth and breadth of experience in supporting companies through regulatory approvals, commercialization, and intellectual property management," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "As we near the potential launch of

    3/25/26 7:30:00 AM ET
    $PCVX
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UPDATE - Bakkt Releases Shareholder Letter and Reports Full Year 2025 Financial Results

    NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Bakkt, Inc. ("Bakkt" or the "Company") (NYSE:BKKT) today released a shareholder letter from Chief Executive Officer Akshay Naheta and reported its financial results for the full year ended December 31, 2025. The Company will discuss its results and 2026 strategic priorities at its Investor Day on March 17, 2026. To our Shareholders: Dear Fellow Shareholders, I am writing to you for the first time as CEO of Bakkt. When I joined the company, it was clear that significant rebuilding was required. Bakkt possessed something rare — a deep regulatory foundation and institutional pedigree rooted in its origins within Intercontinental Exchange — but

    3/16/26 6:49:34 PM ET
    $BKKT
    Finance: Consumer Services
    Finance

    Bakkt Releases Shareholder Letter and Reports Full Year 2025 Financial Results

    NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Bakkt, Inc. ("Bakkt" or the "Company") (NYSE:BKKT) today released a shareholder letter from Chief Executive Officer Akshay Naheta and reported its financial results for the full year ended December 31, 2025. The Company will discuss its results and 2026 strategic priorities at its Investor Day on March 17, 2026. To our Shareholders: Dear Fellow Shareholders, I am writing to you for the first time as CEO of Bakkt. When I joined the company, it was clear that significant rebuilding was required. Bakkt possessed something rare — a deep regulatory foundation and institutional pedigree rooted in its origins within Intercontinental Exchange — but

    3/16/26 6:09:59 PM ET
    $BKKT
    Finance: Consumer Services
    Finance

    $AACG
    $AMBA
    $ANNX
    $APCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:02:53 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:01:40 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Viant Technology Inc.

    SC 13D/A - Viant Technology Inc. (0001828791) (Subject)

    12/6/24 4:08:19 PM ET
    $DSP
    Computer Software: Programming Data Processing
    Technology